Acute Respiratory Distress Syndrome (ARDS) Market 2020 – Revenue Status & Forecast Report 2027 | Faron Pharmaceuticals, BioMarck Pharmaceuticals, GE Healthcare, Hamilton Medical AG

According to the analysis of Reports and Data, the global acute respiratory distress syndrome market was valued at USD 583.8 Million in 2018 and is expected to reach USD 934.8 Million by the year 2026, at a CAGR of 6.0%. Acute respiratory distress syndrome (ARDS) is a type of respiratory failure, which is a form of lung inflammation. Due to which there is a problem with the proper delivery of the oxygen to the different body organs, which at the end impact the appropriate functioning of the parts. Various causes are included with the ARDS, such as sepsis, trauma, pneumonia, and others. The primary treatment for the ARDS involves mechanical ventilation, which is delivered through a rigid tube that enters the oral cavity and is secured in the airway.

This report covers the recent COVID-19 incidence and its impact on Acute Respiratory Distress Syndrome (ARDS) Market. The pandemic has widely affected the economic scenario. This study assesses the current landscape of the ever-evolving business sector and the present and future effects of COVID-19 on the market.

To Request for a PDF Sample, Click Here: - https://www.reportsanddata.com/sample-enquiry-form/2089

Key participants include Faron Pharmaceuticals, BioMarck Pharmaceuticals, GE Healthcare, Hamilton Medical AG, Smiths Medical, Athersys, GlaxoSmithKline, Altor Bioscience, and Mondobiotech.

According to a survey done by the World Health Organization (WHO), it is seen that more than 3 million people are effects due to acute respiratory distress syndrome. It can affect people of all ages. The main reason for the ARDS is air pollution, which is caused due to the emission by the vehicles. The harmful gases emitted are inhaled by the people thus leading to several problems.

Different strategic initiatives have been undertaken by the various players in the ARDS industry. For instance, on December 2018, Windtree Therapeutics, Inc. a biopharmaceutical company merged with CVie Therapeutics and launched AEROSURF, a combination drug/device product which is used to treat respiratory distress syndrome.

For this report, Reports and Data have segmented the acute respiratory distress syndrome market based on device type, injury type, severity, treatment, sales channel, end user and region.

Device Type (Revenue in USD Million; Volume in Tons, 2016–2026)

• Monitoring Devices
• Diagnostic Devices
o Blood Gas Analyzers
o Pulse Oximeters
o Spirometers
o Capnography Devices
o Other Diagnostic Devices
• Therapeutic Devices
o Mechanical Ventilators
 Invasive And Non-invasive Ventilators
o Drug Delivery Devices
 Nebulizers
 Humidifiers
o PAP
o Other Therapeutic Devices

Injury Type (Revenue in USD Million; Volume in Tons, 2016–2026)

• Brain Injury
• Lung Injury

Severity (Revenue in USD Million; Volume in Tons, 2016–2026)

• Mild
• Moderate
• Severe

Grab Your Report at an Impressive Discount! Please Click Here @ https://www.reportsanddata.com/discount-enquiry-form/2089

Treatment (Revenue in USD Million; Volume in Tons, 2016–2026)

• Fibro Proliferate
• Exudative Stage
• Resolution Stage
• Recovery Stage

Sales Channel (Revenue in USD Million; Volume in Tons, 2016–2026)

• Direct Sales
• Channel Sales

End User (Revenue in USD Million; Volume in Tons, 2016–2026)

• Hospitals
• Clinics
• Ambulatory Service Centers
• Other End Users

Regional Outlook (Revenue in USD Million; Volume in Tons, 2016–2026)

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America

Further key findings from the report suggest

• The market for acute respiratory distress syndrome is anticipated to grow at a CAGR of 8.3% in the Asia-Pacific, followed by North America and Europe, with 4.8% and 5.7% CAGR, respectively. Increasing chronic diseases and the rise in air pollution are the key factors to accelerate market growth during the forecast period across all regions.

• As of 2018, the therapeutic device segment was valued at USD 291.9 Million and is expected to grow at a CAGR of 5.8% during the forecast period. Increasing preference for gastrointestinal bleeding and pulmonary fibrosis has been one of the reasons for the growth of the acute respiratory distress syndrome market.

• Due to the ARDS, various complications related to the brain and lung are noticed. Neurological hypoxic brain damage is also one of the injury types, which is reported for acute respiratory distress syndrome.

• The treatment of acute respiratory distress syndrome is Fibro Proliferate, resolution stage, recovery stage, and many more.

• The Asia-Pacific is the largest region for the acute respiratory distress syndrome market due to the significant contribution from countries like China, Japan, India, and Korea due to the growing end-segment and sales channel industries.

• Asia Pacific region is accounted for the third largest market share in 2017, due to consumption in well establishes and end-user segment industries.

• Among the region, North America has the largest market share. The primary driver for the acute respiratory distress syndrome market in North America is the growing brain injury, thus owing to the increase in injury type segment for the ARDS market.

Access the Entire Report packed with TOC, Tables and Figures and Outline of Prominent Companies @ https://www.reportsanddata.com/report-detail/acute-respiratory-distress-syndrome-ards-market

Key selling points of this research study

1. The study gives an in-depth evaluation of the evolving competitive scenario that gives the reader/client a competitive edge.

2. It offers a holistic view of all critical aspects boosting or limiting the growth of the sector

3. The market intelligence report derives an eight-year forecast, including historical, contemporary, and potential market prospects, projecting the estimated progress of the market.

4. It aids informed decision-making by offering an exhaustive database of the pivotal market segments and sub-segments.

Contact Us:

John Watson
Head of Business Development
Reports and Data
40 Wall St. 28th floor New York City, NY 10005 United States
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

This release was published on openPR.